Ultra-sensitive niche Cavidi offers Exazym, an add-on reagent system that enables ultra-sensitive detection of low-abundance biomarkers within standard immunoassay workflows, presenting a compelling value proposition for labs seeking higher sensitivity without overhauling existing protocols.

Global biomarker reach Products are used worldwide by researchers across basic, transitional, and pre-clinical biomarker studies, signaling broad applicability and potential for expanding into adjacent translational research markets and contract research organizations.

SME-scale opportunity With a small-to-midsize employee base and revenue in the low single-digit millions, Cavidi is well-positioned for targeted sales campaigns to boutique biotech firms, university core facilities, and regional labs seeking scalable, cost-effective sensitivity enhancements.

Quality and tech fit ISO 9001 certification and a tech stack oriented toward reliable web and data infrastructure suggest readiness for customer-facing platforms, onboarding, and technical support capabilities that can be leveraged in onboarding services and field demonstrations.

Strategic partnerships potential Recent press highlights a clear market push around Exazym since its May 2021 launch; potential partnerships with diagnostic developers, CROs, or instrument manufacturers could accelerate adoption within HIV and broader immunodiagnostics markets.